IMM-27M

N/A

Report date: 2025/07/22 20:00:10

Base Information

Drug NameIMM-27M
Drug Alias NameIMM27MIMM-27MSYN27MSYN-27M
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionCytotoxic T-Lymphocyte-Associated Antigen 4 inhibitors
TargetsCytotoxic T-Lymphocyte-Associated Antigen 4
Therapy Area/IndicationsSolid tumoursPathologic ProcessesCarcinoma, Non-Small-Cell Lung +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesInstil Bio IncImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd
Inactive CompaniesAxion Bio Inc
Active IndicationsSolid tumoursPathologic ProcessesCarcinoma, Non-Small-Cell Lung +[4] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A